Wells Fargo & Company Sab Biotherapeutics, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.62 - $1.0 $16 - $26	26 Added 9.7%	294 $0
Q3 2023 Nov 13, 2023	BUY	$0.47 - $0.9 $9 - $18	21 Added 8.5%	268 $0
Q2 2023 Aug 15, 2023	BUY	$0.38 - $1.09 $22 - $65	60 Added 32.09%	247 $0
Q1 2023 May 12, 2023	BUY	$0.42 - $0.75 $0 - $1	2 Added 1.08%	187 $0
Q4 2022 Feb 13, 2023	BUY	$0.54 - $9.8 $2 - $49	5 Added 2.78%	185 $0
Q3 2022 Nov 14, 2022	BUY	$0.13 - $12.4 $1 - $161	13 Added 7.78%	180 $0
Q2 2022 Aug 12, 2022	BUY	$1.11 - $3.46 $185 - $577	167 New	167 $0

529K

Ticker SABS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,030,900
Market Cap $172M
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.